Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1297-1305

  Hirsch, A ^a   Vander Els, N ^a   Straus, D J ^a   Gomez, E G ^a   Leung, D ^a   Portlock, C S ^a   Yahalom, J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG FUNCTION TEST; LUNG TOXICITY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 0029912399     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1297     Document Type: Article

References (51)

1. Carmel RJ, Kaplan HS: Mantle irradiation in Hodgkin's disease: An analysis of technique, tumor eradication, and complications. Cancer 37:2813-2825, 1976
2. Gross N: Pulmonary effects of radiation therapy. Ann Intern Med 86:81-92, 1977
3. Morgan G, Freeman A, McLean R, et al: Late cardiac, thyroid, and pulmonary sequelae of mantle radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 11:1925-1931, 1985
4. Shapiro S, Shapiro S, Mill W, et al: Prospective study of long-term pulmonary manifestations of mantle irradiation. Int J Radiat Oncol Biol Phys 19:707-714, 1990
5. Smith L, Mendenhall N, Cicale M, et al: Results of a prospective study evaluating the effects of mantle irradiation on pulmonary function. Int J Radiat Oncol Biol Phys 16:79-84, 1989
6. Watchie J, Coleman C, Raffin T, et al: Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease. Int J Radiat Oncol Biol Phys 13:517-524, 1987
7. Comis R: Bleomycin pulmonary toxicity: Current status and future directions. Semin Oncol 19:64-70, 1992
8. Einhorn L, Krause M, Hornback N, et al: Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell cancer. Cancer 37:2414-2416, 1976
9. Samuels M, Johnson D, Holoye P, et al: Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA 235:1117-1120, 1976
10. Takabe Y, Miyamoto T, Watanabe M, et al: Synergism of x-rays and bleomycin on Ehrlich ascites tumour cells. Br J Cancer 36:391-395, 1977
11. Jorgensen S: Time-dose relationships in combined bleomycin treatment and radiotherapy. Eur J Cancer 8:531-534, 1972
12. Chapman R, Sutcliffe S, Malpas J: Cytotoxic-induced ovarian failure in women with Hodgkin's disease. JAMA 242:1877-1902, 1979
13. DaCunha M, Meistrich M, Fuller L: Recovery of spermatogenesis after treatment for Hodgkin's disease: Limiting dose of MOPP chemotherapy. J Clin Oncol 2:571-577, 1984
14. Kaldor J, Day N, Clarke E, et al: Leukemia following Hodgkin's disease. N Engl J Med 322:7-13, 1990
15. Boivin J, Hutchison G, Lubin J, et al: Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69:1241-1247, 1992
16. Hancock S, Tucker M, Hoppe R: Breast cancer after treatment for Hodgkin's disease. J Natl Cancer Inst 85:25-31, 1993
17. Tucker M, Coleman C, Cox R, et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81, 1987
18. Swerdlow A, Douglas A, Vaughan Hudson G, et al: Risk of second primary cancers after Hodgkin's disease by type of treatment: Analysis of 2,846 patients in the British National Lymphoma Investigation. Br Med J 304:1137-1143, 1992
19. Bonadonna G: Chemotherapy strategies to improve the control of Hodgkin's disease: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 42:4309-4320, 1982
20. Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 96:139-143, 1982
21. Santoro A, Bonadonna G, Valagussa P, et al: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
22. Canellos G, Anderson J, Propert K: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
23. Hoppe R: Radiation therapy in the management of Hodgkin's Disease. Semin Oncol 17:704-715, 1990
24. Knudson R, Lebowitz M, Holberg C, et al: Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127:725-734, 1983
25. Ogilvie C, Forster R, Blakemore W: A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 36:1-17, 1957
26. Bates D, Macklem P, Christie R: An Introduction to the integrated study of the lung, in Bates D, Macklem P, Christie R (eds): Respiratory Function in Disease. Philadelphia, PA, Saunders, 1971, pp 93-94
27. Ichikawa T: Studies of bleomycin: Discovery of its clinical effect, combination treatment with blemycin and radiotherapy side effects and long-term survival. Jpn J Cancer Res 19:99-115, 1976
28. Stover D: Pulmonary toxicity, in DeVita VJ, Hellman S, Rosenberg S (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 2362-2370
29. Denholm E, Phan S: The effects of bleomycin on alveolar macrophage growth factor secretion. Am J Pathol 134:355-363, 1989
30. Khalil N, Bereznay O, Sporn M, et al: Macrophage production of transforming growth factor β and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med 170:727-737, 1989
31. Piguet P, Collart M, Grau G, et al: Tumor necrosis factor/ cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 170:655-663, 1989
32. Comis R, Kuppinger M, Ginsberg S, et al: Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res 39:5076-5080, 1979
33. Sorensen P, Rossing N, Rorth M: Carbon monoxide diffusing capacity: A reliable indicator of bleomycin-induced pulmonary toxicity. Eur J Respir Dis 66:333-340, 1985
34. Hall E: Radiobiology for the Radiologist. Hagerstown, MD, Harper & Row, 1994
35. Rubin P, Casarett G: Clinical Radiation Pathology. Philadelphia, PA, Saunders, 1968
36. Rubin P, Finkelstein J, McDonald S, et al: The identification of new early molecular mechanisms in the pathogenesis of radiation. Int J Radiat Oncol Biol Phys 21:163, 1991 (Suppl 1)
37. Rubin P, Finkelstein J, Shapiro D: Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: Interrelationship between the alveolar macrophage and the septal fibroblast. Int J Radiat Oncol Biol Phys 24:93-101, 1992
38. Castellino RA, Glatstein E, Turbow MM, et al: Latent radiation injury of lungs or heart activated by steroid withdrawl. Ann Intern Med 80:593-599, 1974
39. Evans R, Sagerman R, Ringrose T, et al: Pulmonary function following mantle-field irradiation for Hodgkin's disease. Radiology 111:729-731, 1974
40. Horning S, Adhikari A, Rizk N, et al: Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study. J Clin Oncol 12:297-305, 1994
41. Carde P, Hagenbeek A, Hayat M: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258-2272, 1993
42. Catane R, Schwade J, Turrisi AI, et al: Pulmonary toxicity after radiation and bleomycin: A review. Int J Radiat Oncol Biol Phys 5:1513-1518, 1979
43. Eghbali H, Bonichon F, David B, et al: Combination of ABVD and radiotherapy in early stages of Hodgkin's disease: Analysis of a series of 94 patients. Radiother Oncol 18:127-136, 1990
44. LaGrange J, Thyss A, Caldani C, et al: Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement. Bull Cancer 75:801-806, 1988
45. Brice P, Tredaniel J, Monsuez J, et al: Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease. Ann Oncol 2:73-76, 1991
46. Horning S, Hoppe R, Hancock S, et al: VBM: An effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 6:1822-1831, 1988
47. Bates N, Williams M, Bessell E, et al: Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: A British National Lymphoma Investigation pilot study. J Clin Oncol 12:288-296, 1994
48. Phillips T, Wharam M, Margolis L: Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer 35:1678-1684, 1975
49. Yarnold J, Horwich A, Duchesne G, et al: The influence of sequence and timing of drugs and radiation on the appearance of normal tissue damage. Radiother Oncol 1:91-99, 1983
50. Sorhage F, White D, Straus D, et al: Upper airway obstruction (UAO) in Hodgkin's disease (HD): Incidence and significance of flow volume loop (FVL) abnormalities. Am J Respir Crit Care Med 149:A1014, 1994
51. Wernley J, DeMaester T, Kirchner P, et al: Clinical value of quantitative ventilation-perfusion lung scans in the surgical management of bronchogenic carcinoma. J Thorac Cardiovasc Surg 80:535-543, 1980